Company Overview

Valneva SE is a specialty vaccine company focused on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. The company operates primarily in the biotechnology and vaccine industries, with activities spanning vaccine research, clinical development, industrial manufacturing, and global commercialization. Valneva’s core revenue drivers include commercial vaccine sales, collaboration agreements, licensing arrangements, and milestone payments tied to development partnerships. Its marketed products include vaccines for Japanese encephalitis, cholera, and chikungunya, alongside a pipeline targeting Lyme disease and other infectious diseases.

The company serves public health agencies, travelers, military organizations, and commercial healthcare markets across multiple regions. Valneva has positioned itself as a specialized vaccine developer with expertise in both traditional and next-generation vaccine technologies, including inactivated vaccines and adjuvanted formulations. Originally formed through the merger of Intercell AG and Vivalis SA in 2013, Valneva expanded from a regional European biotech company into an internationally active vaccine manufacturer with integrated research, manufacturing, and commercial operations.

Business Operations

Valneva organizes its operations around vaccine development and commercial vaccine sales. Its principal commercial products include IXIARO/JESPECT for Japanese encephalitis, DUKORAL for cholera and travelers’ diarrhea prevention, and IXCHIQ, a chikungunya vaccine approved in several jurisdictions. The company generates revenue through product sales, research collaborations, licensing income, and government-supported development agreements. Valneva maintains manufacturing capabilities in Europe and has invested in scalable vaccine production infrastructure to support both commercial supply and pipeline expansion.

The company operates internationally, with activities across Europe, North America, and selected markets in Asia-Pacific and Latin America. Key partnerships have included collaborations with Pfizer for Lyme disease vaccine development and prior arrangements with government agencies and global health organizations. Valneva also controls specialized vaccine manufacturing assets and proprietary technologies related to viral and bacterial vaccine production. Public filings and investor disclosures identify integrated R&D, regulatory, and manufacturing capabilities as central components of its operating model.

Strategic Position & Investments

Valneva’s strategic direction centers on expanding its commercial vaccine portfolio while advancing late-stage vaccine candidates targeting infectious diseases with limited preventive options. A major strategic initiative has been the co-development of a Lyme disease vaccine candidate with Pfizer, which has progressed through advanced clinical evaluation. The company has also emphasized the expansion of its travel vaccine franchise and the commercialization of its chikungunya vaccine in multiple global markets following regulatory approvals.

The company has made substantial investments in manufacturing capacity, clinical development programs, and regulatory expansion efforts. Valneva’s portfolio includes both commercialized vaccines and development-stage assets focused on mosquito-borne and bacterial infectious diseases. Management has highlighted differentiated expertise in vaccine platforms and niche infectious disease markets as a competitive advantage. Publicly available disclosures indicate continued prioritization of strategic partnerships, disciplined capital allocation, and geographic commercialization expansion.

Geographic Footprint

Valneva is headquartered in Saint-Herblain, France, and maintains operational facilities in France, Austria, Sweden, the United Kingdom, and the United States. Its manufacturing and research activities are concentrated primarily in Europe, while commercial distribution extends globally through direct sales operations and distribution partnerships. The company’s vaccine products are marketed in multiple countries across Europe, North America, and selected international markets.

The company’s international footprint is supported by collaborations with pharmaceutical partners, government agencies, and healthcare distributors. Valneva has pursued regulatory approvals in several major healthcare markets, including the United States, European Union, and additional international jurisdictions. Its operational model combines centralized vaccine development and manufacturing with globally distributed commercialization and licensing arrangements.

Leadership & Governance

Valneva is governed by a management team with experience in biotechnology, vaccine development, manufacturing, and global pharmaceuticals. The company’s leadership has consistently emphasized innovation in infectious disease prevention, operational scalability, and long-term value creation through strategic vaccine partnerships and commercialization execution. Governance oversight is provided through its executive leadership and board structure consistent with publicly listed European biotechnology companies.

Key executives include:

• Thomas Lingelbach – Chief Executive Officer
• Peter Bühler – Chief Financial Officer
• Juan Carlos Jaramillo – Chief Medical Officer
• Franck Grimaud – President and Chief Business Officer
• Dietmar Katinger – Executive Vice President, Research and Development
• David Lawrence – Chief Business Development Officer

The company’s leadership strategy has focused on balancing commercial vaccine revenues with investment in late-stage clinical programs and strategic alliances. Public company disclosures, including SEC filings and annual reports, indicate an emphasis on disciplined growth, global regulatory expansion, and leveraging specialized vaccine expertise in underserved infectious disease markets.